CR7575A - Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario - Google Patents

Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario

Info

Publication number
CR7575A
CR7575A CR7575A CR7575A CR7575A CR 7575 A CR7575 A CR 7575A CR 7575 A CR7575 A CR 7575A CR 7575 A CR7575 A CR 7575A CR 7575 A CR7575 A CR 7575A
Authority
CR
Costa Rica
Prior art keywords
docetaxel
cyclophosphamide
therapy
breast
cancer
Prior art date
Application number
CR7575A
Other languages
English (en)
Inventor
Chakroun Hichem
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of CR7575A publication Critical patent/CR7575A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a un metodo de terapia adyuvente en el tratamiento de cancer de mama u ovario metastatico, que comprende admnistrar seis ciclos de docetaxel, doxorrubicina y ciclofosfamida a una paciente que los necesita, en el que dichas dosis tiene un efecto terapeutico marcado cuando se compara con otras terapias adyuvantes.
CR7575A 2002-05-17 2004-11-17 Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario CR7575A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38085002P 2002-05-17 2002-05-17

Publications (1)

Publication Number Publication Date
CR7575A true CR7575A (es) 2006-05-10

Family

ID=29550025

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7575A CR7575A (es) 2002-05-17 2004-11-17 Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario

Country Status (28)

Country Link
US (2) US20040014694A1 (es)
EP (1) EP1507573A1 (es)
JP (1) JP4773719B2 (es)
KR (1) KR20050000544A (es)
CN (1) CN1652845A (es)
AU (1) AU2003244646B2 (es)
BR (1) BR0310026A (es)
CA (1) CA2486124A1 (es)
CR (1) CR7575A (es)
EC (1) ECSP045433A (es)
HR (1) HRPK20041072B3 (es)
IL (1) IL165214A0 (es)
MA (1) MA27417A1 (es)
ME (2) MEP16308A (es)
MX (1) MXPA04010640A (es)
MY (1) MY146533A (es)
NO (1) NO20045370L (es)
NZ (1) NZ535992A (es)
OA (1) OA12819A (es)
PA (1) PA8574001A1 (es)
RS (1) RS96304A (es)
RU (1) RU2321396C2 (es)
TN (1) TNSN04217A1 (es)
TW (1) TWI374741B (es)
UA (1) UA81628C2 (es)
UY (1) UY27812A1 (es)
WO (1) WO2003097164A1 (es)
ZA (1) ZA200408549B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2263694B1 (en) * 2003-09-25 2013-06-12 Astellas Pharma Inc. Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
RU2265440C2 (ru) * 2004-01-13 2005-12-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ предоперационного лечения рака молочной железы
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7776832B2 (en) * 2006-04-21 2010-08-17 Gem Pharmaceuticals, Llc Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
US20080085879A1 (en) * 2006-08-31 2008-04-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
BR112013025410A2 (pt) * 2011-04-01 2016-12-20 Astrazeneca Ab tratamento terapêutico
MY194408A (en) 2011-10-14 2022-11-30 Genentech Inc Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
CA2856646C (en) 2011-11-30 2020-01-14 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US20160067182A1 (en) * 2013-04-09 2016-03-10 Merrimack Pharmaceuticals, Inc. Methods and compositions for improving outcomes of liposomal chemotherapy
RU2020120593A (ru) 2014-04-25 2020-09-01 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
MX376122B (es) 2015-07-13 2025-03-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina.
WO2017068227A1 (es) * 2015-10-22 2017-04-27 Universidade De Santiago De Compostela Métodos para utilizar reguladores de aumento de la expresión o activación de p53 y/o reguladores de disminución o inhibidores de la expresión de p63-alfa para el tratamiento de nafld (enfermedad de hígado graso no-alcohólico) y/o nash (esteatohepatitis no- alcohólica)
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
BR112018074990A2 (pt) 2016-06-06 2019-03-12 Beyondspring Pharmaceuticals, Inc. composição, usos e método para reduzir neutropenia
WO2018039452A1 (en) * 2016-08-24 2018-03-01 The Wistar Institute Of Anatomy And Biology Methods of treating cancers with chemotherapy with reduced toxicity
US11491147B2 (en) * 2016-10-03 2022-11-08 Indiana University Research And Technology Corporation Combination drug therapy reduces PARP-1 related DNA repair and increases the efficacy of genotoxic agents
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
EP3576733A4 (en) * 2017-02-01 2020-11-25 Beyondspring Pharmaceuticals, Inc. NEUTROPENIA REDUCTION METHOD
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
AU2019288813B2 (en) * 2018-06-22 2023-06-29 Hendrix College Methods and compositions for inhibition of dihydroorotate dehydrogenase
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN115969792A (zh) * 2023-01-29 2023-04-18 常州金远药业制造有限公司 一种紫杉烷类药物与环磷酰胺共载载药脂质体制备方法
CN116870019A (zh) * 2023-02-03 2023-10-13 大连理工大学 一种具有协同增效作用的药物组合物及其在癌症化疗中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer

Also Published As

Publication number Publication date
TWI374741B (en) 2012-10-21
RU2321396C2 (ru) 2008-04-10
IL165214A0 (en) 2005-12-18
RU2004136984A (ru) 2005-06-27
TNSN04217A1 (en) 2007-03-12
BR0310026A (pt) 2005-02-15
UA81628C2 (uk) 2008-01-25
HRPK20041072B3 (hr) 2007-07-31
HRP20041072A2 (en) 2005-06-30
US20040014694A1 (en) 2004-01-22
OA12819A (en) 2006-07-10
TW200407152A (en) 2004-05-16
AU2003244646B2 (en) 2008-08-07
RS96304A (sr) 2006-10-27
CN1652845A (zh) 2005-08-10
MA27417A1 (fr) 2005-07-01
MXPA04010640A (es) 2005-08-16
ME00055B (me) 2010-10-10
AU2003244646A1 (en) 2003-12-02
MY146533A (en) 2012-08-15
ECSP045433A (es) 2005-01-03
NZ535992A (en) 2008-11-28
CA2486124A1 (en) 2003-11-27
ZA200408549B (en) 2006-01-25
JP2005529925A (ja) 2005-10-06
NO20045370L (no) 2004-12-08
PA8574001A1 (es) 2003-12-19
US20070265213A1 (en) 2007-11-15
WO2003097164A1 (en) 2003-11-27
UY27812A1 (es) 2003-11-28
MEP16308A (en) 2010-06-10
EP1507573A1 (en) 2005-02-23
KR20050000544A (ko) 2005-01-05
JP4773719B2 (ja) 2011-09-14

Similar Documents

Publication Publication Date Title
CR7575A (es) Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario
NO20032027L (no) Effektive antitumorbehandlinger
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
AR105027A1 (es) Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
EA200700686A1 (ru) Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии
PT1325739E (pt) Lipossomas que encapsulam farmacos anti-cancerigenos e sua utilizacao no tratamento de tumores malignos
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
ATE294585T1 (de) Vorbeugung von kolorektalkrebs
AR025718A1 (es) Metodo para reducir el riesgo de cancer
NZ760040A (en) Methods of treating brain tumors using combination therapy
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
AR048068A1 (es) Piperazinas derivadas de urea para el tratamiento de endometriosis
DE60317537T8 (de) Präoperative behandlung von brustkrebs
UA44635A (uk) Спосіб імунотерапії раку молочної залози
DOP2003000756A (es) Administracion de una combinacion de una indolinona con un agente quimioterapeutico para los trastornos de la proliferacion celular
ATE444072T1 (de) Prävention von epithelzellkarzinom
AR043241A1 (es) Terapia combinada que comprende un derivado de indolpirrol-carbazol y otro agente antitumoral
TH102680A (th) การใช้โดซีแทกเซล/ดอกโซรูบิซิน/ไซโคลฟอสฟาไมด์ ในการรักษาแบบเสริม
UA38352A (uk) Засіб для лікувальних ванн
BR0307979A (pt) Método e preparação farmacêutica para reduzir as toxicidades gastrointestinais induzidas por terapia citoablatica , e método para melhorar terapia citoablativa de câncer